유파틸린의 위암 전이 저해효과에 대한 연구

Abstract

Extracts of the whole herb of Artemisia asiatica Nakai (Asteraceae) are used in traditional oriental medicine to treat inflammation. Eupatilin (5,7-dihydroxy-3’,4’,6-trimethoxyflavone) is one of the pharmacologically active components found in Artemisia asiatica, and has been shown to possess anti-tumoral effects in some malignancies, including gastric cancer. However, its anti-metastatic effect in gastric cancer is hardly known. In this study, anti-metastatic effect of eupatilin was investigated in the human gastric cancer cell line, MKN1. Eupatilin inhibited MKN1 growth in a dose- and a time-dependent manner, and induced apoptosis with a concomitant increase of caspase-3 activity. ELISA demonstrated that release of pro-inflammatory cytokines (IL-1, TNFα, IL-6 and IL-8) was significantly reduced by eupatilin. And phospho-AKT and phospho-ERK (p44/42) was reduced. Expression level of β-catenin and integrin was reduced and phospho-GSK was increased. In transcription reporter system, the activity of the transcriptional factor, NF-κB was reduced by eupatilin and the expression of p65 was down-regulated when MKN1 cells were treated with eupatilin. Moreover, a zymography study revealed that this reduction in invasive potential resulted from a reduction in type IV collagenolytic (gelatinolytic) activity. The expressions of metalloproteinases (MMP-2 and MMP-9) were also reduced in MKN1 cells treated with eupatilin. In vitro invasion assay, eupatilin inhibited MKN1 penetrating reconstituted basement membrane barriers. These results suggest that eupatilin inhibits the MKN1 gastric cancer cell proliferation via activation of caspase-3 and the metastatic potential of gastric cancer cells via down-regulation of NF-κB activity followed by reduction of pro-inflammatory cytokine mediated MMPs expressions.